RecruitingPhase 4NCT05858619
Molecular Signatures of Cutaneous Dupilumab Response
Sponsor
University of California, San Francisco
Enrollment
15 participants
Start Date
Feb 1, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Dupilumab for people with atopic dermatitis. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGDupilumab
dupilumab 600 mg injection initially and then 300 mg every other week
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05858619
Related Trials
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
NCT072629831 location
Studies of Skin Microbes in Healthy People and in People With Skin Conditions
NCT006058781 location
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
NCT0639791116 locations
Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases
NCT065994111 location
Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares
NCT076458204 locations